secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-07-23T11:30:22+00:00
Accession:  0001213900-26-080622
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex commences participant screening in Phase 2 DReAMzz study of IHL-42X for obstructive sleep apnea
--------------------------------------------------------------------------------

- First clinical sites approved and actively screening participants for DReAMzz Phase 2 dose confirmation study of IHL-42X.
- IHL-42X has FDA Fast Track designation, supporting potentially expedited regulatory pathway.
- Prior Phase 2 data showed up to 83% reduction in AHI and significant improvements in patient-reported outcomes.
- No FDA-approved oral pharmaceutical therapies currently available for OSA, affecting ~1 billion people globally.
- Study designed to optimize dosing profile and strengthen regulatory package ahead of planned Phase III development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/0001213900-26-080622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea0298674-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-080622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer